68083-618 : Midazolam In Sodium Chloride 1 mg/ml Intravenous Injection, Solution


NDC: 68083-618
Labeler: Gland Pharma Limited
Product Type: Human Prescription Drug
Drug Name:  Midazolam In Sodium Chloride
Dosage Form: Intravenous Injection, Solution
Application #: ANDA218993
Rev. Date: 
CSA Schedule: CIV (US) [1]


[1] Schedule IV Controlled Substance: Low potential for abuse relative to substances in Schedule III. Examples include Alprazolam (Xanax), Diazepam (Valium), Carisoprodol (Soma), Clonazepam (Klonopin), Lorazepam (Ativan), Clorazepate (Tranxene), Midazolam (Versed), Temazepam (Restoril), and Triazolam (Halcion).. More Details: US Dept of Justice Controlled Substance Schedules.

NDC Package Codes:

  • 68083-618-10: 10 POUCH IN 1 CARTON (68083‑618‑10) / 1 BAG IN 1 POUCH / 50 ML IN 1 BAG

Active Ingredients:

  • Midazolam Hydrochloride

Dosage Strength:

  • 1 mg/mL

Pharmaceutical Classes:

  • Benzodiazepine [EPC]
  • Benzodiazepines [CS]

Related Products:

Based on records with the same trade name.
  • 68083-619 Midazolam In Sodium Chloride 1 mg/ml Intravenous Injection, Solution by Gland Pharma Limited
  • 0143-9379 Midazolam In Sodium Chloride 1 mg/ml Intravenous Injection by Hikma Pharmaceuticals USA Inc.
  • 0143-9380 Midazolam In Sodium Chloride 1 mg/ml Intravenous Injection by Hikma Pharmaceuticals USA Inc.
  • 62778-348 Midazolam In Sodium Chloride 1 mg/ml Intravenous Injection by Hikma Farmaceutica
  • 62778-349 Midazolam In Sodium Chloride 1 mg/ml Intravenous Injection by Hikma Farmaceutica

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 68083-618 QR Code

< Prev: 68083-615Next: 68083-619 >




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.